Here, we use the pan-KRAS inhibitors BI-2865 and BI-2493 to show an antiproliferative response in a range of WT KRAS–amplified [copy number (CN) > 7] preclinical cancer models, confirming that amplification represents a KRAS oncogenic driver alteration. The gene discussed is KRAS; the disease is cancer.